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Background: Standard of care for patients with high-grade soft-tissue sarcoma (STS) are 
being redefined since neoadjuvant chemotherapy (NAC) has demonstrated a positive effect on 
patients’ outcome. Yet, response evaluation in clinical trials still remains on RECIST criteria. 
Purpose: To investigate the added value of a Delta-radiomics approach for early response 
prediction in patients with STS undergoing NAC 
Study type: Retrospective 
Population: 65 adult patients with newly-diagnosed, locally-advanced, histologically proven 
high-grade STS of trunk and extremities. All were treated by anthracycline-based NAC 
followed by surgery and had available MRI at baseline and after 2 cycles. 
Field strength/Sequence: Pre- and post-contrast enhanced T1-weighted imaging (T1-WI), 
turbo spin echo T2-WI at 1.5T. 
Assessment: A threshold of <10% viable cells on surgical specimen defined good response 
(Good-HR). Two senior radiologists performed a semantic analysis of the MRI. After 3D 
manual segmentation of tumors at baseline and early evaluation, and standardization of voxel-
sizes and intensities, absolute changes in 33 texture and shape features were calculated. 
Statistical tests: Classification models based on logistic regression, support vector machine, 
k-nearest neighbors and random forests were elaborated using cross-validation (training and 
validation) on 50 patients (‘training cohort’) and was validated on 15 other patients (‘test 
cohort’). 
Results: 16 patients were good-HR. Neither RECIST status, nor semantic radiological 
variables were associated with response except an edema decrease (p=0.003) although 14 
shape and texture features were (range of p-values: 0.002-0.037). On the training cohort, the 
highest diagnostic performances were obtained with random forests built on 3 features: 
Δ_Histogram_Entropy, Δ_Elongation, Δ_Surrounding_Edema, which provided: 
AUROC=0.86, accuracy=88.1%, sensitivity=94.1%, specificity=66.3%. On the test cohort, 




Data conclusions: A T2-based Delta-Radiomics approach can improve early response 
prediction in STS patients with a limited number of features. 
Level of evidence: 3 
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AUROC: area under the ROC curve 
CE: contrast-enhanced 
DCE-MRI: dynamic contrast enhanced MRI 
DWI: diffusion weighted imaging 
FS: fat sat 
KNN: K-nearest neighbors 
LD: longest diameter 
LR: logistic regression 
NAC: neoadjuvant chemotherapy 
NPV: negative predictive value 
PPV: positive predictive value 
RECIST: response evaluation criteria in solid tumors 
RF: random forests  
SI: signal intensity 
STS: soft-tissue sarcoma 
SUVmax: maximal standardized uptake value 
SVM: support vector machine 
TSE: turbo spin echo 











Standard of care for locally advanced high-grade soft-tissue sarcomas (STS) has been recently 
redefined as phase 3 clinical trials demonstrated improved overall and metastasis-free 
survivals in patients treated with anthracycline-based NAC1-3. Despite encouraging results of 
18Fluorodeoxyglucose position emission tomography (18F-FDG-PET-CT), modified Choi 
criteria and dynamic-contrast enhanced MRI (DCE-MRI), evaluation of response to NAC still 
relies on RECIST 1.14.  
Non-invasive quantification of tumor heterogeneity and its changing phenotype during 
treatment is a recent, promising and challenging field of research referred to as radiomics. 
Radiomics techniques aim at leveraging big-data analytics and personalized medicine 
approaches in oncologic imaging5,6. To achieve this, several numeric features are extracted to 
quantify and to screen tumor phenotype and surrounding tissue on any available imaging 
modality7. After a careful selection of features, machine learning algorithms can be designed 
and trained to answer crucial oncologic questions such as associations between imaging 
phenotypes and molecular subtypes with specific treatment and outcomes, prediction of 
response and patient outcome by including other –omics (genomic, transcriptomics) 
information within the model8. 
Because of their complex morphology, architecture and changes during treatments, STS may 
be particularly appropriate to the radiomics approach. Indeed, radiomics on DWI may help to 
improve STS grading on microbiopsy9. In addition, Hayano et al. have demonstrated that 
texture parameters on CT-scan were associated with neoangiogenesis and overall survival for 
STS treated with radiotherapy and bevacizumab10,11. STS heterogeneity assessed on 18F-FDG-
PET-CT may be more predictive of survival as compared to classical measure of maximal 
standardized uptake value (SUVmax)12. Recently, composite texture features from MRI and 
from 18F-FDG-PET-CT have enabled to identify aggressive tumors at risk of lung metastasis 
at baseline13. Together, these promising studies highlight the potential of radiomics applied to 
STS. However, to our knowledge, applications to response prediction to NAC have never 
been attempted. 
Visual MRI evaluation of STS during NAC can highlight a wide range of morphologic 




or selection of resistant component. As change in longest diameter (LD) is not a sufficient 
criterion to predict therapeutic response, we hypothesized that a radiomics process could help 




MATERIALS AND METHODS  
Patients 
The institutional review board approved this study and informed consent was waived. 
All consecutive adult patients between June 2007 and June 2017 were included, as they 
presented with histologically proven high-grade STS of extremities or trunk wall, without 
metastasis on chest CT-scan, eligible for an anthracycline-based NAC according to the 
regional sarcoma reference center board. High-grade was defined as grade III STS according 
to the French Federation of Cancer Centers Sarcoma Group grading system14. 
Criteria for inclusion were: measurable tumor with MRI, available MRI performed <28 days 
before the first cycle of NAC (: baseline, MRI_0) and between cycle 2 and 3 of NAC (: early 
evaluation, MRI_1), 4 to 6 cycles of NAC, histological response assessment on surgical 
specimen by an expert pathologist following published guidelines15. A threshold of <10% of 
viable cells assessed on whole tumor defined good histological response (good-HR)16. 
Of the 163 patients with a newly diagnosed STS of trunk wall and extremities who underwent 
NAC at our institution (according to the pharmacology department), 28 patients were 
excluded because of non-anthracycline-based NAC, 20 because of less than 4 cycles of NAC, 
33 because T2-weighted-imaging (T2-WI) was not performed at baseline, 7 because T2-WI 




Images were acquired in daily practice using 1.5-Tesla MR-systems from different 
radiological centers. Ninety-three examinations (72%) were carried out on a Magnetom 
AERA, (Siemens Healthineers, Erlangen, Germany). Coils, field-of-view and matrices were 
adapted to tumor location and size. To be considered as ‘diagnostic’, MRI must include at 
least 2D T2-WI turbo-spin echo (TSE) sequence without fat-suppression, T1-WI before and 
after Gadolinium-chelates injection (contrast-enhanced T1-WI, CE-T1-WI) and 2 orthogonal 
acquisition plans. Section thickness ranged from 3 to 5 mm. Ranges of repetition time / echo 





Semantic radiological features 
Two senior radiologists (AC and MK, with 3 and 27 years of experience in STS imaging, 
respectively), independently reviewed the MRI blinded to patient data in a randomized 
fashion on a dedicated PACS workstation. They reported: 
- LD in mm on MRI_0 and MRI_1, relative change in LD and RECIST response status. 
- Percentage of tumor volume with changes compatible with fibrosis (low signal intensity (SI) 
on T2-WI, T1-WI, subtle enhancement) and/or necrosis (fluid-like SI on T2-WI, variable SI 
on T1-WI, no enhancement), as follows: 0%, <50% and ≥50%,  
- Change in margin definition on CE-T1-WI (Δ_Margin_Definition), as follows: ‘well-
defined or better definition’ versus ‘stable ill-defined margins or worst’, 
- Change in surrounding edema on T2-WI without or with fat-suppression technique when 
available (Δ_Edema), as follows: ‘none or decreased’ versus ‘stable or increased’, 
- Changes in peritumoral enhancement on CE-T1-WI (Δ_Peritumoral_enhancement), as 
follows: ‘none or decreased’ versus ‘stable or increased’. 
One radiologist (AC) did a second reading 1.5 months later to assess intra-observer agreement 
(Supplemental Data). A consensual lecture was performed 3 months after for the statistical 
analysis.  
 
MRI post-processing (Fi. 1) 
Slice-by-slice 3D-delineation of whole tumor was manually made on T2-WI by one 
radiologist (AC) using the ROI manager of OSIRIX software.  
All slices were resampled using bi-linear interpolation to obtain a common isotropic in plane 
1x1 mm2 pixel aspect. Signal intensities on T2-WI were normalized for non-uniform intensity 
(bias field correction17) and the intensity ranges were standardized using histogram-
matching18 with the acquisition of a healthy volunteer’s thigh as reference. Thirty-three first- 
and second-order texture and shape features were computed using in-house Python software 
based on the ITK library19. The collected features and methods are detailed in Supplemental 
Data. We calculated the absolute change of a given feature ‘X’ for each patient as follows: 
Δ_X=  XMRI_1 – XMRI_0. 
 
Statistical analyses 
Comparisons between good-HR and poor-HR were assessed with Student or Mann-Whitney 
tests depending on results to the Shapiro-Wilk normality test. Association of categorical and 




between features were assessed with Spearman’s rank test. All tests were two-tailed. A p-
value ≤0.05 was deemed significant. 
To elaborate and validate the prediction model, the whole data set was partitioned in two: a 
training cohort (50 patients, included from June 2007 to June 2016) and a test cohort (15 
patients, from July 2016 to June 2017 whose MRI were acquired after the initiation of the 
project). We initially selected only one feature per category (semantic, shape and texture 
categories) according to its lowest p-value at univariate analysis and lowest correlation with 
other significant features.  
The selected combination of features was used to define models with 10-fold stratified cross 
validation on the training cohort. First, for each run and each set, the missing values were 
imputed with training features median and quantitative features were normalized by removing 
the training mean and scaling to unit variance. Several classification algorithms were 
evaluated using the scikit-learn library20:  random forests (RF), k-nearest neighbors (KNN),  
support vector machine (SVM) and logistic regression (LR). The parameters of those 
estimators were optimized by cross-validated grid-search (Supplemental Data). The selected 
classifiers were then trained with the whole 50-patients set and applied on the 15 patients 
from the test set using the same preprocessing method (Figure 1c). 
The cross-validation step was repeated 100 times with shuffled folds composition. The full 
process (including the final test) was also repeated with different random initialization seed 
for the RF algorithm. Average test metrics are reported for each step: accuracy, area under the 
ROC curve (AUROC), specificity, sensitivity, positive predictive value (PPV), negative 
predictive value (NPV) and train score. 
Finally, we increased the number of features that were included in the model in a forward 
stepwise fashion according to their p-value at univariate analysis and we calculated the 
corresponding classifiers test metrics. 
 
RESULTS  
Patient characteristics  (Table 1) 
The cohort included 65 patients (27 females, mean age: 57.9 ± 12.8 years old), of which 16 
(24.6%) were good-HR. The most frequent histotypes were undifferentiated sarcoma (50.8%), 
followed by myogenic sarcoma (leiomyosarcoma and rhabdomyosarcoma, 20%). Most of 
them were deep-seated (93.8%) in the lower limb (58.5%). Twenty-two patients (33.8%) 
received 4 cycles of NAC in total.  
 




No association was found between baseline epidemiologic characteristics and histological 
response. LD at baseline was significantly higher in good-HR (146 ± 66 mm vs. 110 ± 51 
mm, p=0.038). Relative change in LD at early evaluation was also significantly different 
between good-HR and poor-HR (-11.2 ± 20.8% versus 2.9 ± 19.5%, p=0.027), however, 
response status according to RECIST 1.1 was not associated with histological response 
(p=0.112) as most good-HR and poor-HR were classified as stable disease by these criteria 
(81.3% and 79.6%, respectively). Of all the semantic radiological features, only Δ_Edema 
was associated with response (p=0.003), with substantial inter- and intra-rater agreements 
(0.637 and 0.769, respectively). 
 
Radiomics assessment 
The population study was partitioned in a training cohort (50 patients, 11 Good-HR) and a test 
set (15 patients, 5 Good-HR). There was no statistical difference between the training and test 
cohorts regarding the baseline epidemiological characteristics (Supplemental Data).  
Within the training cohort, changes in twelve first and second order textural indices were 
associated with response at univariate analysis: Δ_Histogram_Entropy (p=0.002), Δ_Stdev 
(p=0.008), Δ_ClusterProminence_5 (p=0.038), Δ_Energy_1 (p=0.015), Δ_Energy_2 
(p=0.014), Δ_Energy_5 (p=0.010), Δ_Entropy_1 (p=0.005), Δ_Entropy_2 (p=0.004), 
Δ_Entropy_5 (p=0.003), Δ_Homogeneity_1 (p=0.037), Δ_Homogeneity_2 (p=0.022), 
Δ_Homogeneity_5 (p=0.014), as well as two shape features: Δ_Elongation (p=0.019) and 
Δ_Flatness (p=0.019) (Table 3). Correlation matrix demonstrated significant and strong 
correlations between all first and second order texture features (Table 4). Since the lowest p-
value was obtained with Δ_Histogram_Entropy for texture features and Δ_Elongation for 
shape features, the initial selection for building the model included these two features and 
Δ_Edema 
Table 5 provides the performance of the classifiers for their optimal set of parameters and for 
this selection. On the training set, the highest mean accuracy was obtained with RF (88.1%), 
followed by LR (85.8%), KNN (80.5%) and SVM (75.2%). In an objective response setting, 
RECIST 1.1 provided one of the lowest accuracy with 76.0% of correctly predicted patients. 
In descending order, AUROC were 0.87 with LR, 0.86 with RF, 0.81 with KNN, 0.67 with 
SVM and 0.66 for relative change in LD (Fig. 2).  
In the test set, the accuracy of the prediction of the 15 patients for classifiers trained with the 
whole training set on the 3 initial features were:  74.6% for RF, 66.7% for LR, 53% for SVM, 




while 9 (90%) of poor-HR were correctly predicted with RF, 3 (60%) good HR were 
systematically misclassified in the test set.  
Since the best compromise was obtained with the RF classifier, we investigated the impact of 
adding features in the RF model (Fig. 3).  Accuracy and AUROC were not improved in the 
training cohort and they decreased in the test cohort. In the training cohort, specificity was at 
its highest with 3 features while sensitivity remained constant. In the test cohort, higher 
sensitivity and specificity were obtained with 3 features. Figure 4 illustrates the added value 
of the final RF algorithm for two cases with a stable disease according to RECIST 1.1, one 
being a poor-HR, the other a good-HR.  
The retrospective analysis of the false positive predictions made by the RF model highlighted 
cases of massively necrotic-hemorrhagic tumors and late-responder profiles (Fig. 5). 
Quantification of tumor heterogeneity was biased by heterogeneous large blood clots on 
baseline examination and their changes at early evaluation. Analysis based on other imaging 
modalities of ‘late-responder’ cases did not provide any clue to predict a good response after 
2 cycles, whereas pre-surgical evaluation demonstrated extensive fibro-necrotic changes, 




In this study, we developed and evaluated radiomics models to predict the histological 
response of STS during NAC that were based on changes on T2-WI from baseline to early 
evaluation. Overall, our best model was obtained with RF classifiers on 3 relevant features 
from analysis of STS shape, heterogeneity and surrounding tissue. It performed better than 
RECIST 1.1 with an accuracy of 88.1% and AUROC of 0.86 at cross-validation and had the 
highest scores on the independent test cohort. However, those last results highlighted outliers 
requiring additional characterization. 
 
Performances of our best predictive model were comparable or higher than those found for 
other imaging biomarkers in literature although we should be careful in making comparisons 
since different cut-offs may have been used to define a good histological response, different 
chemotherapy regimens may have been prescribed and imaging may have been performed at 
different stages in time. Stacchiotti et al. investigated CHOI criteria to predict a pathological 
very good response defined as <10% viable cells on surgical specimen in a series of 37 
patients.  They obtained an accuracy of 74.1% (14/22 CHOI partial responders being true 




decrease in contrast-enhancement of -30.5% between two MRI with optimized acquisition 
delay after contrast-agent injection provided an accuracy of 82.8%23. On a retrospective series 
of 23 patients, multiparametric assessment combining qualitative evaluation of diffusion 
imaging and DCE-MRI provided a best AUROC of 0.83324. At early evaluation with 18F-
FDG-PET-CT, a decrease >35% of SUVmax provided an AUROC of 0.83 in a prospective 
study of 50 patients25,26. 
Association between decrease in edema and good response did not surprise us. Surrounding 
edema is associated with high-grade STS and satellite tumor cells27-29. NAC efficacy should 
logically go with reduced satellite tumor cells and thus a decrease of signal anomalies 
surrounding STS on MRI. A decrease in tumor cellularity turning into fibro-necrotic tissue 
could explain a tumor softening leading to changes in shape, towards retraction of its borders. 
Finally, these fibro-necrotic processes lead to a larger range of signal intensity values within 
tumors, that is to say a flattening of the SI histogram responsible for change in its entropy. 
A careful retrospective analysis of the tumors that were systematically ill classified in our 
series enabled to identify ‘late-responder’ and ‘massively necrotic STS’ profiles. These last 
ones are difficult to image and their morphological changes during treatment can be 
complicated to interpret. Evaluation with RECIST 1.1 is biased as it mostly measures the 
necrosis and not the changes in viable tumor component. DCE-MRI and diffusion imaging are 
challenging because viable tissue generally consists in small buds attached to the tumor wall 
within a large hemorrhagic mass. In our case, 18F-FDG-PET-CT correctly predicted a good 
response according to the previously published cut-off of a 35-38% decrease in SUVmax26. 
These two observations from the test cohort provide insights into next features to add to the 
future predictive models. Partitioning dataset in independent training and test datasets enabled 
to have a larger view of the response patterns of STS, and to consider additional imaging 
features from other advanced imaging modalities for improvement of the future models.  
Interestingly, our best models relied on a limited set of features from non-contrast enhanced 
sequences. Corino et al. also found that only 3 features from diffusion imaging provided the 
highest accuracy to predict histological grade of STS9. The best model to predict lung 
metastatic relapse of STS according to Vallières et al. relied on 4 texture features13. In their 
studies, adding any other feature to the model did not improve prediction. In a context of 
controversy about long-term effects of Gadolinium-chelates contrast agents, an imaging 
work-flow for response evaluation may be considered in which known outliers of the model 
or patients with an intermediate probability of response could be assessed in a second step 






Our study has limits. First, this is a retrospective study with a relatively small number of 
patients. Nevertheless, our series is one of the largest regarding STS and MRI, with uniformly 
treated patients with the chemotherapy of reference. No epidemiological data was added into 
the model because none was associated with the tumor response at univariate analysis. 
Indeed, the population study only included patients who shared all the epidemiological 
features associated with worse prognosis, namely high-grade, deep- or deep and superficial 
STS with LD above 5cm30. Beside, if modest, the cohort was significant enough to put a few 
data aside to form an independent validation set and control our results. 
Second, imaging protocols were not designed for radiomics studies. 2D TSE T2-WI was used 
for features extraction because (i) it was the most commonly acquired sequence, (ii) it 
provided a large range of morphological changes during treatment, (iii) there was no change 
in the acquisition parameters during the study period. T2-WI can capture fibrotic and necrotic 
processes (decreased and increased T2 SI, respectively). T2-WI has already demonstrated 
good results in textural approaches applied to other tumor types31-35. Conversely, post-contrast 
T1-WI sequences showed heterogeneous acquisition protocols in our series: some were 3D 
gradient recalled echo imaging and others 2D TSE, different fat suppression techniques were 
used (Dixon method, fat-sat, short TI inversion recovery, subtraction with pre-contrast T1-
WI), as well as different contrast agents. Furthermore, the acquisition delay after contrast 
agent injection was not standardized although it may have a significant effect on changes in 
tumor heterogeneity quantified on CE-T1-WI. Changes in surrounding edema helped predict 
response but its assessment could only be qualitative because of non-standardized sequence 
for its evaluation. Future studies should include automatic and quantitative assessment of 
edema and its changes, since it was one of the best predictor for the response in the current 
study. Adding another imaging modalities would have markedly decreased the population 
study and we made the decision to privilege one informative sequence and an acceptable 
population study. Nevertheless, this point stresses the urge for a standardized MRI protocol 
for STS. 
Third, post-processing included voxel size standardization - with an acceptable voxel size to 
preserve the global shape of tumor - and signal intensity normalization. The aim was to limit 
the inherent bias due to MR acquisition at different stages on different MR-systems and to 
improve the reliability and the reproducibility of the extracted features. 3D Segmentation was 
manually performed, slice-by-slice. Automatic and semi-automatic methods were tried before 
the study with disappointing results as compared to those obtained by the expert radiologist 




Fourth, we decided to limit the number of extracted textural features, despite the fact that 
several others could have been calculated from fractal analysis, wavelet, and other matrices36. 
Therefore, we limited the risk of finding relevant features by chance and facilitated the 
understanding of our results. Those we calculated are widely used and can be easily found in 
open libraries37. Due to the relatively small population study, we did not apply deep-learning 
purposely and focused on time-tested classifiers.  Finally, one could question the outcome. 
The histological response is routinely used as an intermediate evaluator reflecting immediate 
efficacy of NAC and patient prognosis16. Nonetheless, it is a semi-quantitative assessment, 
with possible subjectivity and sample bias. Ultimately, our goal is to build predictive models 
for survival, but only 41 patients in this series have a follow-up of more than 2 years and 26 
of more than 5 years. 
 
To conclude, our preliminary results indicate that T2-based delta-radiomics approach applied 
to STS in the neoadjuvant setting is feasible, provides valuable information to predict 
response after only 2 cycles and improves evaluation compared to RECIST 1.1. Optimization 
of the model is still needed with the study of larger cohorts and inclusion of other categories 
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TABLE 1. Epidemiologic characteristics  
 
Characteristics Patients (n=65) 
Gender Male 38 (58.5) 
 Female 27 (41.5) 
Age at diagnosis (y), mean ± sd 57.9 ± 12.8 
Histotype Undifferentiated sarcoma1 33 (50.8) 
 Muscular sarcoma2 13 (20) 
 M/RC liposarcoma3 5 (7.7) 
 Other liposarcoma4 6 (9.2) 
 Synovial sarcoma 7 (10.8) 
 MPNST 1 (1.5) 
Location Trunk wall 12 (18.5) 
 Pelvic Girdle 2 (3.1) 
 Shoulder Girdle 6 (9.2) 
 Upper limb 7 (10.8) 
 Lower limb 38 (58.5) 
Depth Superficial 4 (6.2) 
 Deep 61 (93.8) 
LD at baseline (mm), mean ± sd 119 ± 56 
Nb cycles 4 cycles 22 (33.8) 
 5 or 6 cycles 43 (66.2) 
LD indicates longest diameter, sd indicates standard deviation, MPNST indicates malignant peripheral nerve 
sheath tumor.  
Data are numbers of patients with percentages in parentheses, except for age and LD.  
1 : myxofibrosarcoma or undifferentiated sarcoma ;  
2 : leiomyosarcoma and rhabdomyosarcoma ;  
3 : myxoid/round cells liposarcoma ;  













TABLE 2. Association between demographic and semantic radiological features and 
histological response. 
 
Variables Good_HR Poor_HR p-value 
Baseline clinico-radiological features       
 Gender    
  Male 11 (68.8) 27 (55.1) 0.393 
 
 Female 5 (21.2) 22 (44.9) 
  Age at diagnosis (y) 58.8 ± 11.4 57.6 ± 13.3 0.873 
 Histotype    
 
 Undifferentiated sarcoma
1 10 (62.5) 23 (46.9) 
0.257 
  Muscular sarcoma2 5 (21.2) 8 (16.3) 
  M/RC liposarcoma3 1 (6.3) 4 (8.2) 
  Other liposarcoma4 0 (0) 6 (12.2) 
  Synovial sarcoma 0 (0) 7 (14.3) 
  MPNST 0 (0) 1 (2.1) 
  Location       
    Trunk wall 2 (12.5) 10 (20.4) 
0.146 
    Pelvic Girdle 2 (12.5) 0 (0) 
    Shoulder Girdle 1 (6.3) 5 (10.2) 
    Upper limb 2 (12.5) 5 (10.2) 
    Lower limb 9 (56.2) 29 (59.2) 
 Depth    
 
 Superficial 1 (6.3) 3 (6.1) 1.000   Deep 15 (93.7) 46 (93.9) 
  Nb cycles       
    4 cycles 11 (68.8) 32 (65.3) 1.000 
    5 or 6 cycles 5 (21.2) 17 (34.7) 
 LD on MRI_0 (mm) 146 (66) 110 (51) 0.038 * 
MRI_0 to MRI_1       
 Change in LD (%) -11.2 ± 20.8 2.9 ± 19.5 0.027 * 
  RECIST 1.1       
    Complete Response 0 (0) 0 (0) 
0.112 
    Partial Response 3 (18.8) 3 (6.1%) 
    Stable Disease 13 (81.2) 39 (79.6) 
    Progressive Disease 0 (0) 7 (14.3) 
 Objective Response    
 
 Yes 3 (18.8) 3 (6.1) 0.154   No 13 (81.2) 46 (93.9) 
  Δ_Margin_definition§       
    Well- or better limited 5 (21.2) 9 (20) 0.490 
    stable or worst 11 (68.8) 36 (80) 
 Δ_Edema    
 
 None or decrease 12 (75) 15 (30.6) 0.003 **   Stable or increase 4 (25) 34 (69.4) 
  Δ_Peritumoral enhancement§       
    None or decrease 12 (80) 24 (57.1) 0.134 
    Stable or increase 3 (20) 18 (42.9) 
 Fibro-Necrotic Changes    
 
 No 2 (21.2) 14 (25.6) 
0.430   < 50% tumor volume 9 (56.2) 23 (46.9) 
    ≥ 50% tumor volume 5 (31.3) 12 (24.5) 
LD indicates longest diameter, sd insdicates standard deviation. MPNST indicates malignant peripheral nerve 
sheath tumor. 
Data are numbers of patients with percentages in parentheses, except for age, LD and change in LD.  
1 : myxofibrosarcoma or undifferentiated sarcoma ;  
2 : leiomyosarcoma and rhabdomyosarcoma ;  
3 : myxoid/round cells liposarcoma ;  
4 : pleomorphic or dedifferentiated liposarcoma.  
§: 8 patients had missing values for Δ_Peritumoral_enhancement and 4 for Δ_Margin_definition due to defective 
MR protocol (incomplete acquisition of edema on post contrast T1-WI, different acquisition plan on MRI_0 and 




TABLE 3. Association between delta-radiomics features and response in training cohort 
 
Variables Good-HR Poor-HR p-value 
1st order feature    
 Δ_Histogram_Entropy -0.185 ± 0.548 0.316 ± 0.406 0.002 ** 
 Δ_Interval -0.037 ± 0.179 0.017 ± 0.260 0.524 
 Δ_Kurtosis 2.967± 10.329 -8.16 ± 24.83 0.056 
 Δ_Mean -0.071 ± 0.269 -0.078 ± 0.223 0.879 
 Δ_Skewness -0.015 ± 1.725 0.488 ± 2.261 0.598 
 Δ_Stdev -0.001 ± 0.094 0.090 ± 0.096 0.008 ** 
2nd order features    
 Δ_ClusterProminence_1 496.6 ± 5280.8 6004 ± 10585 0.070 
 Δ_ClusterProminence_2 -366.7 ± 5075.7 5096 ± 8913 0.051 
 Δ_ClusterProminence_5 -816.9 ± 4070.6 3654 ± 6244 0.038 * 
 Δ_ClusterShade_1 -154.97 ± 376.63 -86.6 ± 480.8 0.666 
 Δ_ClusterShade_2 -134.0 ± 347.6 -74.3 ± 410.9 0.631 
 Δ_ClusterShade_5 -97.1 ± 278.1 -56.3 ± 294.4 0.648 
 Δ_Energy_1 0.066 ± 0.134 -0.06 ± 0.104 0.015 * 
 Δ_Energy_2 0.065 ± 0.126 -0.053 ± 0.096 0.014 * 
 Δ_Energy_5 0.059 ± 0.118 -0.047 ± 0.089 0.010 * 
 Δ_Entropy_1 -0.392 ± 1.474 0.945 ± 1.282 0.005 ** 
 Δ_Entropy_2 -0.461 ± 1.559 0.984 ± 1.355 0.004 ** 
 Δ_Entropy_5 -0.545 ± 1.596 0.988 ± 1.414 0.003 ** 
 Δ_Homogeneity_1 0.001 ± 0.123 -0.083 ± 0.113 0.037 ** 
 Δ_Homogeneity_2 0.014 ± 0.144 -0.093 ± 0.130 0.022 * 
 Δ_Homogeneity_5 0.030 ± 0.160 -0.100 ± 0.146 0.014 ** 
 Δ_Inertia_1 0.916 ± 1.431 1.843 ± 2.316 0.256 
 Δ_Inertia_2 1.587 ± 3.089 3.799 ± 4.640 0.137 
 Δ_Inertia_5 1.579 ± 5.708 6.992 ± 8.608 0.056 
Shape features    
 Δ_Pixels_number 6695 ± 41169 2747 ± 80507 0.078 
 Δ_Elongation -0.081 ± 0.181 0.064 ± 0.191 0.019 * 
 Δ_Equivalent_spherical_radius -2.065 ± 7.797 0.328 ± 10.323 0.266 
 Δ_Roundness -0.025 ± 0.051 -0.015 ± 0.083 0.714 
 Δ_Perimeter -20.517 ± 12737 1303 ± 16842 0.810 
 Δ_Physical_size -19716 ± 209957 31197 ± 391970 0.355 
 Δ_Flatness 0.200 ± 0.281 0.029 ± 0.249 0.019 * 
 Δ_Perimeter_on_border_ratio -0.003 ± 0.006 0.002 ± 0.013 0.183 
  Δ_Feret_diameter -3.033 ± 23.707 5.45 ± 33.16 0.202 
Data are given as mean and standard deviation.  




















TABLE 5. Diagnostic performance of the classifiers on the 3 selected features for training 
and test cohorts (respectively cross-validation and final test steps). 
 
Classifiers Accuracy AUROC Sensitivity  Specificity PPV  NPV  Train Score 
Training Cohort        
 Random Forest 88.1 (87.6-88.5) 0.86 (0.86-0.87) 94.1 (93.8-94.4) 66.3 (64.7-67.8) 90.9 (90.5-91.2) 76.2 (75.0-77.3) 0.98  
 K-nearest neighbors 80.5 (80.2-80.7) 0.81 (0.81-0.82) 97.3 (97.1-97.4) 20.5 (19.5-21.4) 81.3 (81.1-81.5) 66.9 (65.1-68.8) 1.00 
 Support Vector Machines 75.2 (74.5-75.8) 0.67 (0.66-0.68) 85.4 (84.7-86.2) 37.9 (36.5-39.3) 83.0 (82.6-83.3) 42.8 (41.3-44.4) 0.96  
 Logistic Regression 85.8 (85.6-86.0) 0.87 (0.86-0.87) 94.8 (94.8-94.9) 53.2 (52.5-53.9) 87.8 (87.6-87.9) 74.4 (74.1-74.7) 0.87 
 RECIST 1.1§ 76.0 0.66  57.0 90.9 66.7 21.3 _ 
Test Cohort        
 Random Forest 74.6 (73.7-75.5) 0.63 (0.62-0.63) 98.0 (97.2-98.8) 27.8 (25.9-29.7) 73.1 (72.6-73.7) 90.8 (87.2-94.5) 0.98  
 K-nearest neighbours 66.7 0.53 100.0 0.0 66.7 0.0 1.00 
 Support Vector Machines 53.3 0.52 80.0 0.0 61.5 0.0 0.98 
 Logistic Regression 66.7 0.46 90.0 20.0 69.2 50.0 0.86 
  RECIST 1.1§ 73.3  0.72  90.0 40.0 75.0 66.6 _ 
 
AUROC indicates area under the ROC curve, PPV indicates positive predictive value, NPV indicates negative 
predictive value.  
Accuracy, sensitivity, specificity, PPV and NPV are given in percentage with 95% confidence interval in 
parentheses. 
§ Statistics are given for RECIST 1.1 in an objective response setting, that is to say ‘complete response or partial 
response’ vs. ‘stable disease or progressive disease’. AUROC corresponded to AUROC of relative change in 















FIGURE LEGENDS  
FIGURE 1: Radiomics pipeline. (a) First step consisted in MRI post-processing, including 
resampling (with a bi-linear interpolation), bias removal (N4) and normalization of signal intensities 
(with histogram-matching). The volume of interest was manually segmented, slice by slice, and then 
propagated on post-processed images, enabling the extraction of histogram-based, texture and shape 
features (b). This process was applied on baseline MRI and MRI after 2 cycles of neoadjuvant 
chemotherapy providing delta-radiomics features (Δ_features), which were rescaled (standard scaling). 
(c) Statistical method. In step 1, the whole data set was partitioned into a ‘Training Cohort’ and a ‘Test 
Cohort’. In step 2, the ‘Training cohort’ was used to build the model. It was based on a 10-fold cross-
validation that consisted in separating the 50 patients into 10 blocks of 5 patients. For each of the 10 
combinations, the classifier was trained on the subset of 9 blocks (blue squares), then validated on the 
remaining block (in light orange). At the end of the cross-validation, each block has been used once 
for validation (*). This whole process was repeated with different tuning parameters proper to each 
type of classifier (: hyperparameters, Supplemental Data) and different methods for features selection 
and preprocessing, until obtaining a model with the highest accuracy and area under the ROC curve 
(AUROC). Those optimal metrics are shown in the cross-validation section of the results. In step 3, a 
model with the optimal combination of parameters was fitted on the whole training cohort. This final 
model was tested on the independent test cohort (dark orange) and its diagnostic performance 
(accuracy, AUROC, PPV, NPV, specificity, sensitivity, negative/predictive value) was calculated. 
 
FIGURE 2: ROC curves of random forest model, logistic regression model and relative change 
in longest diameter from baseline to post-2 cycles of chemotherapy (% Change_LD) at cross-
validation. Random forest and logistic regression were based on the optimal selection of features 
(Change in surrounding edema, change in histogram-entropy, change in Elongation). For each 
classifier, the individual scores of each sample from all folds are sorted together into a single ROC 
curve and then averaged across the 100 repetitions.  
 
FIGURE 3. Accuracy, AUROC, sensitivity and specificity of the random forest algorithm as 
functions of the numbers of features included in the model. These statistic metrics were calculated 
in the training cohort (a) and the test cohort (b). Features were added in the ascending order of their p-
value (descending order of statistical significance) as listed in Table 1 and 2. The grey dashed vertical 
line emphasizes the initially selected 3-features model (changes in edema, histogram_entropy and 
elongation from baseline to post-2 cycles evaluation). 
 
FIGURE 4: Added value of final random forest (RF) model for early response prediction.  
(a) 76 years-old male presented with a deep-seated grade III pleomorphic rhabdomyosarcoma of the 
shoulder. After 2 cycles of chemotherapy, the tumor was stable according to RECIST 1.1 criteria, but 
it demonstrated an increase of its surrounding edema (white arrows), stability of its shape and stable 
histogram entropy. Hence, the final RF model predicted a poor histological response that was 
confirmed on surgical specimen (70% residual viable cells). 
(b) 50 years-old male presented with a deep-seated grade III undifferentiated pleomorphic sarcoma of 
the popliteal region. After 2 cycles of chemotherapy, the tumor was stable according to RECIST 1.1 
criteria. Surrounding edema markedly decreased (white arrow heads) with a retraction of its shape on 
3D reconstruction and a decreased entropy on normalized histogram. The final RF model predicted a 
good response that was confirmed on surgical specimen (5% residual viable cells). 
T2: T2-weighted imaging, FS: fat-sat, PD: proton-density weighted-imaging 
 
FIGURE 5: Outliers patients who were misclassified as poor responders by the model. (a) 
Example of massively necrotic tumor at baseline: 52 years-old male presented with deep-seated grade 
III undifferentiated pleomorphic sarcoma of the left thigh. Blood clots and fibrinous septa were mixed 
with necrosis (white arrow), only small buds of tumor were seen against tumor wall. Therefore, 
changes in tumor heterogeneity were mostly due to change in structure and signal of the necrotic-
hemorrhagic compartment. (b) This patient benefited from a 18F-FDG-PET-CT at baseline and after 
two cycles showing a strong decrease of SUVmax (8.16 to 3.94, -51.7%) suggestive of chemotherapy 
efficacy. (c) Example of a ‘late responder’ profile: 66 years-old male presented with a deep-seated 




visual assessment at early evaluation. (d) 18F-FDG-PET-CT demonstrated a slight paradoxical increase 
of SUVmax (22.34 to 24.32) although the patient was a good histological responder after 4 additional 
cycles of chemotherapy. 
T2-WI: T2 weighted imaging; Gd+ FS T1-WI: Fat-Sat T1 weighted imaging after Gadolinium-
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